Treating periodontal disease may reduce prostate inflammation
the ONA take:
According to a new report published in the journal Dentistry, researchers from Case Western Reserve University School of Dental Medicine and the Departments of Urology and Pathology at University Hospitals Case Medical Center in Cleveland, Ohio, have found that treating gum disease reduced symptoms of prostate inflammation.
For the study, researchers enrolled 27 men with confirmed inflammation of the prostate gland and elevated prostate specific antigen (PSA) levels.
All of the men also had moderate to severe gum disease. Of the 27 participants, 21 had no or mild inflammation, 15 had biopsy-confirmed malignancies, and two had inflammation and malignancy. All were then treated for periodontal disease.
Results showed that despite receiving no prostate treatment, 21 of the 27 participants had decreased PSA levels. Researchers found that those with the highest levels of prostate inflammation benefited the most from gum disease treatment.
"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease," said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.
Treating gum disease reduced symptoms of prostate inflammation.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|